A groundbreaking study published in Nature sheds light on the critical role of TET2, a gene often mutated in myeloid malignancies, in suppressing tumor growth. This discovery opens up exciting new avenues for targeted therapies and preventive interventions for blood cancers and age-related diseases.
Understanding TET2 and its Tumor-Suppressing Function
Approximately 30% of individuals with myeloid malignancy diseases, including chronic myelomonocytic leukemia, acute myeloid leukemia, and myelodysplastic syndromes, have a mutation in the TET2 gene. This gene provides instructions for creating proteins crucial for tumor suppression. For years, scientists knew TET2 mutations were linked to these cancers, but the precise mechanisms behind this connection remained elusive.
UT Health San Antonio
From left, Mingjiang Xu, professor of molecular medicine; Ying Li, research assistant, professor of molecular medicine; Juyeong Hong, research scientist of molecular medicine; Feng-Chun Yang, professor of cell systems and anatomy; Juan Wang, research assistant of molecular medicine.
A New Understanding of TET2’s Role
A team led by Mingjiang Xu, a molecular medicine professor at the Joe R. and Teresa Lozano Long School of Medicine at the University of Health Science Center at San Antonio, along with Chuan He from the University of Chicago, uncovered a novel pathway essential for TET2’s tumor-suppressing function. Their research, published in Nature, revealed that TET2 modifies chromatin-associated RNA, leading to changes in gene expression. This finding expands our understanding beyond TET2’s previously known role in DNA modification.
“One thing that surprised us was how powerful this pathway is on TET2-mediated gene expression. It is a quantum structure change mediated by this pathway,” Xu explained.
UT Health San Antonio
Acute myeloid leukemia cells.
The absence of TET2 creates a pathway leading to an open chromatin environment, allowing for gene expression changes that can fuel the growth of blood cancer cells. This discovery identifies MBD6, a protein involved in reading RNA modifications, as a promising therapeutic target for treating myeloid malignancies with TET2 mutations.
Implications for Treatment and Prevention
These findings have significant implications for both treatment and prevention. Currently, there are no specific therapies targeting TET2 mutations. However, this research opens the door to developing targeted therapies that can modulate this pathway and inhibit tumor growth. Moreover, understanding TET2’s role in age-related diseases, such as clonal hematopoiesis of indeterminate potential (CHIP), could lead to preventive interventions for individuals at risk.
“These individuals have a significantly higher possibility of developing myeloid cancer and cardiovascular diseases. This makes our findings even more important because the aging population is growing and these individuals need preventive interventions,” Xu said.
A Collaborative Effort
This groundbreaking work was made possible through the collaborative efforts of researchers at UT Health San Antonio and the University of Chicago. Xu credits the supportive environment at UT Health San Antonio, his dedicated team, and the National Institutes of Health funding for enabling this discovery.
This research represents a major milestone in our understanding of TET2 and its role in cancer development. By targeting the newly identified pathway, researchers hope to develop effective therapies and preventive strategies for individuals with TET2 mutations and related diseases.
**Learn more about the latest advancements in cancer research and explore potential treatment options.**